MMS — Maximus, Inc.

Maximus, Inc. (MMS) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.31 billion, in line with expectations and full-year guidance.
• Adjusted EBITDA Margin: 14.4%, up from 13.7% year-over-year.
• Adjusted EPS: $2.07, compared to $2.01 in the prior year.
• Cash Flow: Operating cash flow of $190 million; free cash flow of $179 million.
• Debt: Total debt decreased slightly to $1.55 billion; net leverage ratio remains at 1.8x.
• Share Repurchases: Approximately 1.4 million shares repurchased for $111 million in Q2, with an additional 600,000 shares for $40 million post-quarter.

2. Strategic Updates and Business Highlights

• Technology Investments: Continued focus on AI and automation, leading to improved operational efficiency and margin enhancement.
• Segment Performance:
  • U.S. Federal Services: Revenue of $753 million; operating income margin improved to 17.6%.
  • U.S. Services: Revenue declined to $416 million, impacted by prior-year clinical volume surges.
  • Outside the U.S.: Revenue of $137 million with an operating loss of $3.1 million.
• Customer Engagement: Strong focus on fraud prevention and program integrity, with technology solutions enhancing service delivery.
• Pipeline: Total sales opportunities at $56.8 billion, with a book-to-bill ratio of 0.5x.

3. Forward Guidance and Outlook

• Fiscal Year 2026 Revenue Guidance: Expected to range between $5.2 billion and $5.35 billion.
• Adjusted EBITDA Margin Guidance: Now approximately 14.2%, a 20 basis point increase.
• Adjusted EPS Guidance: Increased by $0.20 to a range of $8.05 to $8.55, representing 14% year-over-year growth at the midpoint.
• Free Cash Flow Guidance: Reiterated at $450 million to $500 million.

4. Bad News, Challenges, or Points of Concern

• DSO (Days Sales Outstanding): Elevated at 78 days due to administrative delays with a major federal customer, expected to remain high in Q3 before improving in Q4.
• Revenue Declines: U.S. Services segment experienced revenue decline due to prior-year clinical work and state-specific dynamics.
• Competitive Pressures: Challenges in the procurement environment, particularly in federal agencies, with increased delays and protests affecting timelines.

5. Notable Q&A Insights

• DSO Concerns: The elevated DSO is linked to complex invoicing requirements for a major federal customer, with expectations for eventual collection.
• H.R. 1 Opportunities: Positive momentum in SNAP and Medicaid community engagement initiatives, with potential for significant revenue increases.
• Federal Contract Recompete: Uncertainty surrounding the Veterans Benefits Administration (VBA) contract recompete timeline, but confidence in service quality and reputation remains high.
• Technology Adoption: Caution from state customers regarding AI and automation due to compliance concerns, affecting the speed of implementation compared to federal contracts.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Maximus, Inc.'s performance and outlook for Q2 2026.